2022/08/29InnoPharmax have signed supplementary agreement with Shandong New Times Pharmaceuticals for Sapropterin Dihydrochloride. 2022/03/29Patent of “Oral Administration of Unstable or Poorly-Absorbed Drugs (N11005)” was granted in U.S.
Products Anti-infection Agents Contrast Agents Oncology Agents Immunological Agents Drugs for Rare Diseases Active Pharmaceutical Ingredient > > Product and Pipeline > home 資料建置中!!
Chemicalbook提供INNOPHARMAX INC的联系电话和地址信息
Innopharmax.A company profile of Taiwan-based specialty pharmaceutical company Innopharmax is presented, highlighting the company's history, management and ownership background, acquisitions, products, and financial information and financial key ratios.EBSCO_bspInnopharmax...
INNOPHARMAX is a specialty pharmaceutical company focused in the development and commercialization of products for the treatment of oncology and specialty. We internally develop and/or acquire potential drug candidates for further clinical development as well as commercialization. We intend to use internal...
InnoPharmax Received IND Approval from US FDA to Proceed with Clinical Development in Efficacy, Pharmacokinetics and Safety of Gemcitabine Oral Formulation in Biliary Tract Cancer Jul. Signed distribution contract for Inpheno Tablets with BL&H Co. Ltd. for Korea Market Mar. Signed product supply an...
開發中品項 產品線 D07001 GemOral D0191801 Oral Insulin D0282102 Bendamustine RTD 上市產品 抗感染用藥 顯影劑 癌症用藥 免疫用藥 罕見疾病用藥 投資人專區 財務資訊 公司治理 股東專區 聯絡我們 聯絡資訊 人才招募 2025 © INNOPHARMAX. ALL RIGHTS RESERVED.優吉兒網站設計 - Website Info....
本公司口服胰島素配方技術獲日本專利核准 最新消息 最新消息 ■主要內容: 本公司研發N11005(口服胰島素),「不穩定或難吸收藥物之口服投用」發明專利申請案,公開號為2017533239A,已獲日本特許廳(JP)核准。 Back
本公司口服胰島素配方技術取得歐洲及印尼專利許可。 █主要內容:
組織架構 投資人專區 財務資訊 公司基本資料 每月營業額 財務報告 公司治理 董事會 功能委員會 內部稽核 規章辦法 企業社會責任 股東專區 股東會年報 股東會相關資訊 重大訊息 聯絡人資訊 關於因華 因華簡介 因華沿革 組織架構 組織架構 > 關於因華 > 首頁...